Key Developments: Sequenom Inc (SQNM.OQ)

SQNM.OQ on NASDAQ Stock Exchange Global Select Market

2.59USD
17 Apr 2014
Price Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.59
Open
$2.58
Day's High
$2.66
Day's Low
$2.51
Volume
328,713
Avg. Vol
373,607
52-wk High
$4.89
52-wk Low
$1.65

Search Stocks

Latest Key Developments (Source: Significant Developments)

Sequenom Inc announces chief executive officer and chief financial officer changes
Wednesday, 5 Mar 2014 07:00pm EST 

Sequenom Inc:Says that Harry F. Hixson, Jr. will retire as chief executive officer (CEO), effective as of the company's 2014 annual meeting on June 10.William J. Welch, the company's current president and chief operating officer, will assume the role of CEO, effective as of the annual meeting and immediately upon Hixson's retirement as CEO.In addition, Paul V. Maier, chief financial officer (CFO) since 2009, will retire effective as of the annual meeting.Maier will serve as consultant to the company following his retirement.Carolyn D. Beaver, current vice president and chief accounting officer, will assume the role of CFO, effective as of the annual meeting and immediately upon Maier's retirement as CFO.  Full Article

Sequenom Inc's Sequenom Laboratories grants NicOx SA exclusive promotion and marketing rights for its RetnaGene AMD test in North America
Thursday, 16 Jan 2014 01:30am EST 

NicOx SA and Sequenom Inc:Say that their affiliate companies (Nicox Inc. and Sequenom Laboratories) have entered into an exclusive agreement in the age-related macular degeneration (AMD) field.Say Nicox has been granted the North American promotional rights to the Sequenom Laboratories RetnaGene AMD laboratory-developed test, for the evaluation of a patient's risk of AMD disease progression within 2, 5 and 10 years.  Full Article

Sequenom Inc announces issuance of European patent for novel methods of detecting fetal aneuploidy
Wednesday, 8 Jan 2014 05:24pm EST 

Sequenom Inc:Says on Jan. 1, 2014, the European Patent Office (EPO) issued patent EP2183693 B1, entitled Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing, invented by Drs Dennis Lo, Rossa Chiu, and Kwan Chee Chan of The Chinese University of Hong Kong.Says the patent claims novel methods for detecting fetal aneuploidy using sequencing and was the first patent filing made in the EPO directed to such novel methods.Says it holds exclusive rights to the patent, an important part of Sequenom's prenatal diagnostic patent portfolio, with coverage across all countries in the European Union, and also including Liechtenstein, Monaco, Norway and Switzerland.  Full Article

Harwood Feffer LLP Announces Investigation Of Sequenom Inc
Tuesday, 10 Sep 2013 10:02am EDT 

Harwood Feffer LLP announced that it is investigating potential claims against the board of directors of Sequenom Inc, concerning whether the board has breached its fiduciary duties to shareholders. The investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.  Full Article

Robbins Arroyo LLP Announces Investigating Directors And Officers Of Sequenom Inc On Behalf Of Shareholders
Monday, 9 Sep 2013 03:32pm EDT 

Robbins Arroyo LLP announced that it is investigating whether certain officers and directors of Sequenom Inc. breached their fiduciary duties to shareholders. Sequenom provides genetic analysis solutions in the United States and internationally. On July 24, 2013, Sequenom announced the company's financial results for the second quarter of 2013. Despite reporting a 91% increase in total revenues to $34.9 million for the quarter, Sequenom also reported a net loss of $31 million, as compared to a net loss of $29.6 million for the same period in 2012. According to Sequenom, the company suffered from delays in collecting payments as a result of medical coding changes adopted by Medicare, Medicaid, and other third-party payors. Sequenom also revealed that certain payors, including most state Medicaid plans, have yet to implement the new codes and, in some cases, no longer provide coverage for certain tests. On this news, Sequenom's share price fell $1.39 per share, or 30%, to close at $3.30 on July 25, 2013.  Full Article

Sequenom Inc Announces Sequenom CMM's MaterniT21 PLUS Testing Service Received Clinical Laboratory Permit From New York State
Monday, 5 Aug 2013 07:00am EDT 

Sequenom Inc announced that the New York Department of Health's Wadsworth Center Clinical Laboratory Evaluation Program (CLEP) has issued a clinical laboratory permit to allow the Sequenom Center for Molecular Medicine's (Sequenom CMM) San Diego facility to provide its noninvasive prenatal laboratory-developed test, the MaterniT21 PLUS test, to healthcare professionals in the state of New York, effective August 1, 2013. In addition, Sequenom CMM's CLIA laboratory location in North Carolina has received accreditation by the College of American Pathologists (CAP), indicating that it has met all applicable standards required by the organization to provide laboratory services.  Full Article

Sequenom Inc And CombiMatrix Corp Announce Collaboration Agreement To Market Chromosomal Microarray Analysis For Prenatal Testing
Thursday, 1 Aug 2013 07:00am EDT 

Sequenom Inc and CombiMatrix Corp announced that the Sequenom Center for Molecular Medicine LLC (Sequenom CMM) and CombiMatrix have entered into a collaboration agreement to market chromosomal microarray analysis (CMA) testing services to broaden and confirm the results of noninvasive, prenatal testing (NIPT) to physicians and their patients. Under the agreement, the two laboratories will collaboratively use their respective marketing channels and sales forces to promote the use of NIPT and CMA and work together to provide technical training to physicians and counseling, education and support services to physicians and their patients. The two companies plan to provide, when clinically appropriate, a comprehensive test result report for ordering physicians.  Full Article

Law Offices of Howard G. Smith Announces Investigation On Behalf Of Investors Of Sequenom Inc
Thursday, 25 Jul 2013 05:38pm EDT 

Law Offices of Howard G. Smith announced that it is investigating potential claims on behalf of purchasers of the securities of Sequenom, Inc. (Sequenom or the Company) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company between May 9, 2013 and July 24, 2013 concerning Sequenom`s operations and financial performance. Sequenom is a life sciences company that provides genetic analysis solutions, including noninvasive molecular diagnostic tests for prenatal genetic disorders, women`s health-related disorders, and ophthalmologic, oncologic and other medical conditions, in the United States and internationally. On July 24, 2013 Sequenom issued a press release announcing its financial results for the second quarter of 2013 and disclosed that diagnostic revenues accounted for 70% of total revenues in the quarter, versus 76% in the first quarter of 2013.  Full Article

Sequenom Inc Provides Update On Status Of Patent For Methods Of Detecting Fetal Aneuploidy
Friday, 14 Dec 2012 08:00pm EST 

Sequenom Inc announced that the U.S. Patent and Trademark Office has withdrawn the issuance of U.S. Patent No. 8,340,916. Sequenom has been informed by the Patent and Trademark Office that issuance was withdrawn in connection with an anticipated patent interference proceeding between parties with pending patent applications or issued patents directed to similar subject matter. Sequenom had previously been notified that the patent would issue on December 25, 2012, with claims to novel methods for detecting fetal aneuploidy using massively parallel sequencing. The patent is entitled Diagnosing Fetal Chromosomal Aneuploidy Using Massively Parallel Genomic Sequencing and was invented by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the Chinese University of Hong Kong. Sequenom has exclusive rights to this patent.  Full Article

Sequenom Inc Announces Leadership Appointments-DJ
Tuesday, 11 Dec 2012 07:00am EST 

Dow Jones reported that Sequenom, Inc. announced the appointments of William Welch as the Company's President and Chief Operating Officer and Dirk van den Boom as the Company's Executive Vice President, Research & Development and Chief Technology Officer, both effective immediately. Additionally, Ronald Lindsay has been named as the Company's Executive Vice President, Strategic Planning. Harry F. Hixson, Jr. will continue to serve as Chairman and Chief Executive Officer.  Full Article

Search Stocks